Physician profile
Marcus Mcferren
NPI 1891971651
$871,827.76
in general payments reported to CMS, 2019-2025
40 companies · $169K in 2025
The $169K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172K · 2020: $61K · 2021: $66K · 2022: $90K · 2023: $144K · 2024: $169K · 2025: $169K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $407K · Travel and Lodging: $26K · Honoraria: $21K · Food and Beverage: $18K · Consulting Fee: $11K · Education: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $406,833.25 |
| Travel and Lodging | $26,012.62 |
| Honoraria | $20,790.00 |
| Food and Beverage | $17,600.12 |
| Consulting Fee | $10,526.00 |
| Education | $676.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $278,173.89 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Genzyme Corporation | $172,816.12 | 2019-2025 | |
| Dermavant Sciences, INC. | $89,268.37 | 2022-2024 | Vtama |
| Pfizer INC. | $81,422.04 | 2019-2025 | |
| Abbvie INC. | $79,752.26 | 2019-2025 | |
| Amgen INC. | $75,610.58 | 2019-2025 | Otezla, Otezla, Enbrel |
| Celgene Corporation | $30,157.32 | 2019 | |
| Organon LLC | $21,095.61 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $10,635.05 | 2019-2025 | Aklief, Nemluvio |
| Ucb, INC. | $7,587.86 | 2019-2025 | Bimzelx, Cimzia |
| Dermira, INC. | $6,545.98 | 2019-2021 | |
| Leo Pharma INC. | $3,325.18 | 2019-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $3,195.55 | 2019-2025 | Cabtreo, Jublia |
| Arcutis Biotherapeutics, INC. | $3,173.64 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $1,716.98 | 2019-2025 | Tremfya |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Mcferren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.